2022
DOI: 10.1002/cmdc.202200392
|View full text |Cite
|
Sign up to set email alerts
|

Synthesis, Biological Evaluation, and Binding Mode of a New Class of Oncogenic K‐Ras4b Inhibitors

Abstract: Ras proteins are implicated in some of the most common life‐threatening cancers. Despite intense research during the past three decades, progress towards small‐molecule inhibitors of mutant Ras proteins still has been limited. Only recently has significant progress been made, in particular with ligands for binding sites located in the switch II and between the switch I and switch II region of K‐Ras4B. However, the structural diversity of inhibitors identified for those sites to date is narrow. Herein, we show … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2022
2022
2023
2023

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 60 publications
(121 reference statements)
0
1
0
Order By: Relevance
“…The success of covalent inhibition of KRAS­(G12C) to its switch-II pocket (SII-P) (reviewed in , ) is exemplified by the first clinically approved KRAS-targeting drugs sotorasib and adagrasib . , This success has cultivated the currently ongoing efforts to target the SII-P of other KRAS mutants beyond G12C, including G12D, G12S, and G12R . However, a number of other approaches toward direct KRAS targeting with small molecules, such as targeting SI/SII (switch-I/switch-II) site, have mainly resulted in lower-affinity compounds. Therefore, SII-P appears to offer the most promising approach to tackle this oncoprotein with small-molecule inhibitors that have been reported to date.…”
Section: Introductionmentioning
confidence: 99%
“…The success of covalent inhibition of KRAS­(G12C) to its switch-II pocket (SII-P) (reviewed in , ) is exemplified by the first clinically approved KRAS-targeting drugs sotorasib and adagrasib . , This success has cultivated the currently ongoing efforts to target the SII-P of other KRAS mutants beyond G12C, including G12D, G12S, and G12R . However, a number of other approaches toward direct KRAS targeting with small molecules, such as targeting SI/SII (switch-I/switch-II) site, have mainly resulted in lower-affinity compounds. Therefore, SII-P appears to offer the most promising approach to tackle this oncoprotein with small-molecule inhibitors that have been reported to date.…”
Section: Introductionmentioning
confidence: 99%